Search results
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
The Motley Fool via AOL· 4 days agoAmgen is an established big pharma company with a massive pipeline and many avenues for growth outside of obesity, so a future win in that segment would just be the icing on the cake. 2. < ...
Women denied ‘wonder drug’ that could double terminal breast cancer life expectancy
Daily Telegraph· 3 days agoWomen with HER2-low or ultra-low breast cancer who took Enhertu lived without their cancer growing...
Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.
The Wall Street Journal· 5 days agoMore patients can fend off the disease for months or years with targeted or immune-boosting drugs,...
Ionis Pharmaceuticals (IONS) Down 0.7% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 10 hours agoIn the first quarter, Wainua royalty revenues were $1 million. Wainua generated sales of $5 million...
AstraZeneca PLC ADR TradeGate Stock Price Today | NASDAQ AZNPy Live Ticker - Investing.com
Investing.com· 1 day agoRisk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for ...
Lung cancer treatment produces progression-free survival results in Phase III trial
Medical Xpress· 1 day agoOsimertinib, produced by AstraZeneca under the brand name Tagrisso, significantly extends the time patients live without their cancer worsening, offering the first effective ...
Astra's Enhertu breast cancer trial shows 'unprecedented' results
Reuters via AOL· 4 days ago(Reuters) -AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about...
With new Enhertu data, an ADC could overtake chemo in breast cancer
BioPharma Dive via Yahoo Finance· 5 days agoStudy participants had already received one hormone therapy and a type of drug called a CDK 4/6...
Patient’s Dark Fantasy About Aetna Lands Him in Jail
The Daily Beast via Yahoo News· 3 days agoMany Americans loathe their health insurance providers.A majority say they have severe concerns about financial hardship due to medical bills—even with...
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support...
Morningstar· 6 days agoTempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm ...